Use of Isotopically Labelled Substrates Reveals Kinetic Differences Between Human and Bacterial Serine Palmitoyltransferase

Peter J. Harrison¹²³, Kenneth Gable⁴, Niranjanakumari Somashekarappa⁴, Van Kelly¹, David J. Clarke¹, James H. Naismith²³⁵, Teresa M. Dunn⁴ & Dominic J. Campopiano¹*

¹ EastChem School of Chemistry, David Brewster Road, University of Edinburgh, Edinburgh, EH9 3FJ.
² Division of Structural Biology, Wellcome Trust Centre of Human Genomics, Oxford, OX3 7BN.
³ Research Complex at Harwell, Rutherford Appleton Laboratory, Didcot, OX11 0FA.
⁴ Dept. of Biochemistry and Molecular Biology, Uniformed Services University, 4301 Jones Bridge Rd., Bethesda, MD 20814-4799.
⁵ The Rosalind Franklin Institute, Rutherford Appleton Laboratory, Didcot, OX11 0FA.

*To whom correspondence should be addressed: Tel.: 44 131 650 4712; E-mail: Dominic.Campopiano@ed.ac.uk.

Abstract

Isotope labels are frequently used tools to track metabolites through complex biochemical pathways and to discern the mechanisms of enzyme-catalysed reactions. Isotopically-labelled L-serine is often used to monitor the activity of the first enzyme in sphingolipid biosynthesis, serine palmitoyltransferase (SPT) as well as labelling downstream cellular metabolites. Intrigued by the effect that isotope labels may be having on SPT catalysis, we characterised the impact of different L-serine isotopologues on the catalytic activity of recombinant SPT isozymes from humans and the bacterium Sphingomonas paucimobilis. Our data show that S. paucimobilis SPT activity displays a clear isotope effect with [2,3,3-D] L-serine, whereas the human SPT isoform does not.
This suggests that whilst both human and *S. paucimobilis* SPT catalyse the same chemical reaction, there may well be underlying subtle differences in their catalytic mechanisms. Our results suggest that it is that the activating small subunits of human SPT that play a key role in these mechanistic variations. This study also highlight that it is important to consider the type and location of isotope labels on a substrate when they are to be used in *in vitro* and *in vivo* studies.

Sphingolipids (SLs) are a family of L-serine derived molecules that have been shown to play a range of functional roles in various species (1, 2). Their importance is reflected in the expanding list of diseases that are now linked with SLs and their metabolites (3). Serine palmitoyltransferase (SPT) is a pyridoxal 5′-phosphate (PLP) dependent enzyme which catalyses the first step in sphingolipid (SL) biosynthesis, the Claisen-like condensation of L-serine with palmitoyl-CoA to form 3-ketodihydrosphingosine (3-KDS) (Fig. 1A) (4). Although SPT is conserved across all SL-producing organisms studied to date there are structural differences between SPTs from different taxa. In bacteria such as *Sphingomonas paucimobilis* SPT is a soluble homodimer, whose structure was determined in 2007, revealing a three domain architecture (5). Whilst all three domains are required for dimerisation of the enzyme, the central domain is required for catalysis and the active site is formed at the dimer interface (5, 6). In contrast to bacterial isoforms, the SPT homologs from higher eukaryotes are heterodimers of two core subunits, LCB1 and LCB2, also referred to as SPT1 and SPT2. The LCB1 and LCB2 proteins share significant sequence homology suggesting shared ancestry but display key differences in the residues proposed to be involved in PLP binding and enzyme catalysis (7-11).

Moreover, the eukaryotic SPTs are integral membrane proteins that reside in the endoplasmic reticulum (ER) membrane. In humans additional complexity is added by the presence of two isoforms of LCB2, as well as of two isoforms of a third, small subunit of SPT (ssSPTa and ssSPTb), whose functionally-equivalent small protein in *Saccharomyces cerevisiae* is Tsc3p (12, 13). These ssSPTs have a single spanning transmembrane domain and have been shown to increase the *in vitro* activity of the SPT complex by up to ~100-fold (13, 14). To compound this, in eukaryotes, SPT forms a complex with regulatory partners known as the orosomucoid-like protein (ORMs) which are negative regulators of
SPT activity (15, 16). In yeast this complex is called “SPOTS”, consisting of Lcb1, Lcb2, Tsc3p, Orm1, Orm2 and Sac1 (15). The molecular mechanisms by which this complex controls SPT activity are unclear, but phosphorylation of Orm1 and Orm2 by a kinase cascade is in part responsible for the regulation of SPT (15, 16). In humans, the equivalent ORMDL proteins lack the phosphorylation sites found in the yeast ORMs, and so it is unknown how these proteins regulate the activity of SPT (17, 18). A recent study has suggested that the ORMs and ORMDLs respond directly to ceramide concentrations to control SPT enzymatic turnover, but the mechanistic details have yet to be revealed (19). Mutations of both human SPT are also linked with a rare genetic disease hereditary sensory neuropathy type 1 (HSAN1, reviewed in (20)). These mutations result in a gain of function and increased promiscuity with respect to the amino acid specificity of the enzyme; mutant SPTs generate so-called “deoxy sphingolipids” from glycine and L-alanine (21). Despite their acknowledged link to HSAN1, the exact mechanism of how these atypical SLs exert their damage on neurons remains unclear. Also, there is growing evidence that ORMDLs are linked to various disease pathologies but their exact roles are under current investigation (22).

SPT belongs to the α-oxoamine synthase (AOS) family of PLP-dependent enzymes whose enzymology has been extensively studied, and a mechanism has been proposed for SPT (Fig. 1A) (5, 23-27). Catalysis begins with displacement of the active site lysine from the PLP-bound internal aldimine (also known as the holo-) form of the enzyme by the L-serine substrate to generate the SPT PLP:L-serine external aldimine complex. Binding of palmitoyl-CoA is thought to induce a conformational change which allows an active site base to abstract the α-proton of L-serine, forming a substrate quinonoid. Electron rebound from the PLP-bound quinonoid results in C-C bond formation with liberation of free coenzyme A (CoASH). Decarboxylation of the PLP:β-keto acid follows, and the product quinonoid is reprotonated by an active site acid. Displacement by the active site lysine releases the product 3-KDS from the PLP:product external aldimine and returns the SPT to the PLP-bound, holo-form.

Isotope labels are frequently used in metabolic and natural product biosynthesis studies where they can be used to track the incorporation of small molecule precursors into complex metabolites in a cellular environment (28-31). The inherent differences in zero point energies between different isotopes can be
used to elucidate the mechanistic details of enzyme catalysed reactions. This is due to the fact that these energy differences result in increased bond strength which can be observed as an effect on the rate of an enzyme catalysed reaction – a kinetic isotope effect (KIE). As such, this effect has been used to great effect in mechanistic studies (32-35).

Given the increase in the use of isotopically labelled L-serine in SL analysis, especially the use of the [2,3,3-D] L-serine isotopologue (compound (3) in Fig. 1B), we wanted to investigate what effect, if any, these labels have on the SPT catalysed reaction. We were concerned that without an understanding the underlying biochemistry, a misplaced isotope label could lead to unintended consequences for two reasons – 1) incorrect rate measurements and 2) using a mass label that is lost in the reaction. For metabolic tracking, it is advantageous to have as big a mass difference as possible in the products of interest to allow one to clearly differentiate those derived from the labelled-substrate. However, these labels are of no value if they are lost during the enzyme-catalysed steps of a pathway. Herein we report the use of a series of isotopically labelled L-serine substrates and their effects on the kinetics of the SPT catalysed reaction. Our data show that with soluble, homodimeric S. paucimobilis SPT, the presence of a deuterium label on the α-carbon results in a significant KIE, implicating abstraction of this proton as being a rate determining step. In contrast, surprisingly, in the multi-subunit, membrane-bound human homolog of the enzyme, no KIE is observed for the same substrate. Our results are in agreement with a recent report by Hannun and colleagues on the yeast SPT complex (34) and suggest that there are subtle mechanistic differences between the cytoplasmic and membrane-bound forms of the enzymes that are dependent on the activating small subunit.

MATERIALS AND METHODS

Source of L-serine Isotopologues

The structures and labels of the L-serine substrates used are shown in Fig. 1B. Non-isotopically labelled L-serine (1) was purchased from Sigma (Cat #S4500). [3,3-D] L-serine (2) (Cat #DLM-161), [2,3,3-D] L-serine (3) (Cat #DLM-582) and [1,2,3-13C, 2-15N] L-serine (5) (Cat #CNLM-474) were purchased
Expression and Purification of Sphingomonas paucimobilis SPT (SpSPT)

The N-terminal His<sub>6</sub>-tagged SpSPT was expressed in *E. coli* and purified from a pET-28a expression plasmid essentially as previously described (36). Briefly, a single colony was picked into 200 mL of LB media and grown overnight at 37° C with 35 µg mL<sup>-1</sup> kanamycin. The overnight culture was diluted back to OD<sub>600</sub> = 0.05. Cells were grown to OD<sub>600</sub> = 0.6 at 37° C with 35 µg mL<sup>-1</sup> kanamycin. At OD<sub>600</sub> = 0.6, cells were induced with 0.1 mM IPTG and incubated at 30° C for a further 5 hours before harvesting at 4122 x g. Cells were washed in PBS buffer before resuspension in 1:1 (w/v) wash buffer (50 mM HEPES, pH 7.8, 150 mM NaCl, 10 mM imidazole, 25 µM PLP). Cells were lysed by sonication (10 minutes, 30 seconds on, 30 seconds off, 10 microns) and cell free extract was prepared by centrifugation (24 446 x g, 30 minutes). The cell free extract was then applied to a 1 mL His-Trap column (GE Life Sciences) and washed with wash buffer until the base line was flat. SpSPT was then eluted by an imidazole gradient (10 mM – 300 mM) over one hour. Fractions containing protein were pooled and concentrated in a 30 kDa spin filter to a final volume of 1 mL. Concentrated protein was finally purified by gel filtration chromatography (Superdex S200 column, GE Life Sciences), eluting with 50 mM HEPES pH 7.8, 150 mM NaCl, 25 µM PLP. Fractions containing protein were pooled and concentrated in a 30 kDa spin filter, before storage at -80° C. Protein concentrations were determined by the method of Bradford, 1976 (37).

Expression and Purification of Single Chain Human SPT (scSPT)

The construction and expression of an active single chain human SPT (scSPT) has been described previously (14, 17, 38) and a full report on its biochemical and structural characterisation is to follow (Somashekarappa et al., in preparation). This construct contains the three human SPT subunits (LCB2, ssSPTa and LCB1) linked together in a head-to-tail fashion into a single chain protein that can be
expressed in yeast, as well as CHO-LyB and HEK293 mammalian cells. Most recently this construct has also been used in HeLa cells to study SPT regulation (19). The plasmid encoding single chain SPT was used to transform the S. cerevisiae Δtlc1 strain. A single yeast colony was then used to inoculate 200 mL of YPD media which was grown overnight at 26° C. The overnight culture was diluted back to OD_{600} = 0.05 and 0.5 mM CuSO_{4} was added. Cells were grown overnight at 26° C before harvesting at 5000 x g. Harvested cells were washed with PBS before resuspension in buffer (50 mM tris, pH 8.0, 0.25 M sorbitol, 0.3 M NaCl, 2 mM EDTA, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM benzamidine, 25 µM PLP). Cells were lysed by bead-beating (0.5 mm diameter zirconia beads) and cellular debris was removed by centrifugation at 5000 x g. The supernatant was then collected and membranes were harvested by ultracentrifugation at 164 244 x g for one hour. Harvested membranes were washed in membrane buffer (50 mM HEPES pH 8, 150 mM NaCl, 10% glycerol, 1 mM PMSF, 25 µM PLP) before re-harvesting by ultracentrifugation at 164 244 x g for one hour. Membranes were solubilised in 1% n-dodecyl β-D-maltoside (DDM, Generon) for one hour before unsolubilised material was removed by ultracentrifugation at 164 244 x g for one hour. Solubilised protein was added to 1 mL of equilibrated nickel resin (GE Life Sciences) and incubated for one hour at 4° C. Resin was washed with 10 column volumes (CV) wash buffer (50 mM HEPES pH 8, 150 mM NaCl, 30 mM imidazole, 10% glycerol, 1 mM PMSF, 25 µM PLP) before elution into 5 CV elution buffer (0.024% DDM, 50 mM HEPES pH 8, 150 mM NaCl, 300 mM imidazole, 10% glycerol, 1 mM PMSF, 25 µM PLP). The eluted protein was concentrated and stored at -80° C until required.

**Kinetic Analysis of Purified Bacterial SpSPT and Human scSPT**

All assays were conducted in a total volume of 100 µL and were performed using a BioTek Synergy HT plate reader. Assays contained L-serine (100 µM-40 mM), palmitoyl-CoA (250 µM), 5,5′-dithiobis-(2-nitrobenzoic acid), (DTNB, ε_{412}=14,150, 400 µM), SpSPT or scSPT (SpSPT: 400 nM, scSPT: 5 µM), assay buffer (50 mM HEPES, pH 7.8, 100 mM NaCl, (0.05% DDM for scSPT) to 100 µL).
Measurements were taken at 412 nm over the course of one hour. Statistical analysis was performed by unpaired t-test using the GraphPad online calculator (39).

**Long Chain Base (LCB) Formation by Human SPTs in Yeast Microsomes**

Microsomal Membrane Preparation: For these experiments we used two forms of the human SPT complex expressed in yeast microsomes. One was the fused gene construct scSPT described in Section 2.3 without purification. The other used human SPT from yeast microsomes where the human LCB1, LCB2 and ssSPT genes were independently co-expressed as described previously (13). Cells were harvested at exponential phase, pelleted at 5000 x g, washed with water, re-pelleted and then washed with TEGM buffer (50 mM Tris, pH 7.5, 1 mM EGTA, 1 mM β-mercaptoethanol (BME), 1 mM PMSF, 1 μg mL⁻¹ Leupeptin, 1 μg mL⁻¹ Pepstatin A, 1 μg mL⁻¹ Aprotinin) buffer. The cell pellets were resuspended in TEGM buffer at 1 mL / 50 OD₆₀₀ nm cells and glass beads (0.5 mm diameter) were added to ~1/4 inch from the meniscus. The cells were disrupted by vortexing 4 x 1 min with 1 min on ice in between, transferred to a new tube with extensive washing of the beads and pelleted at 8000 x g for 10 min. The supernatant was transferred to new tubes and spun at 100 000 x g for 30 min. The resulting pellet was resuspended by a Dounce homogenizer in at least 10x volume and repelleted at 100 000 x g. The final membrane pellet was resuspended in TEGM buffer containing 33% glycerol and stored at -80° C. Total protein concentration of the microsomal membranes was determined by Bio-Rad dye reagent using IgG as a standard.

**Microsomal SPT Assay**

The reaction was started by adding 400 μg of microsomal membrane to a reaction cocktail (final volume 200 μL) containing 50 mM HEPES, pH 8.1, 50 μM PLP, 10 mM L-serine (1) or deuterated serine stable isotope (2 or 3, Fig. 1B), and 100 μM pentadecanoyl coenzyme-A (Avanti Polar Lipids). After a 10 min reaction at 37° C, 100 μL 2 N NH₄OH and 100 μL 1 M NaBH₄ were added and the reaction kept at 37° C for an additional 10 min. Long chain bases (LCBs) were extracted by the addition of 2.0 mL
CHCl₃:methanol (1:2) containing 250 nM C17-sphingosine as an internal standard, followed by the addition of 1 mL CHCl₃ and 2 mL of 0.5 M NH₄OH, vortexing and centrifuging briefly. The upper aqueous layer was aspirated off and the lower layer was washed with 2 mL of 60 mM KCl and centrifuged. The washing was carried out twice and 1.3 mL of the sample was dried and subjected to derivatization for HPLC analysis.

**Analysis of Long Chain Bases from Microsomal SPT Assays**

The long chain base (LCB) extract was redissolved in 80 μL of methanol: 190 mM triethylamine (20:3) and 20 μL AccQ-Fluor Reagent (Waters). After incubation at room temperature for at least 60 minutes, 10 μL 1.0 M KOH (methanol) was added. 80 μL of the sample (corresponding to 0.24 mg protein) was injected on a Genesis C₁₈ 4 μM HPLC column (Jones Chromatography) and resolved on an Agilent 1100 series HPLC equipped with a fluorescence detector. The LCBs were resolved using an isocratic mobile phase of acetonitrile:methanol:H₂O:acetic acid:triethylamine (48:32:16.5:3.0:0.7) at 1.5 mL min⁻¹ and detected by the AccQ fluorescence (excitation: 244 nm/emission: 398 nm).

**Mass Spectrometry Analysis of 3-KDS Products**

An aliquot (50 μL) from each kinetic assay end point reaction (see section 2.3) was desalted on C₁₈ resin and eluted in 100% acetonitrile. Samples were dried and resuspended in 50% acetonitrile/0.1% formic acid before direct infusion electrospray ionisation mass spectrometry analysis using a TriVersa NanoMate (Advion) coupled to a 12T FTICR (Bruker). Twenty 4-megaword transients were averaged over 200-500 m/z providing a KDS resolution of at least 300,000. Data were analysed using Bruker Compass DataAnalysis 4.4 for detection of compounds and their accurate monoisotopic masses. The theoretical isotope envelope was predicted using empirical formula and the Bruker IsotopePattern tool. Raw data was exported using Bruker CompassXport for re-plotting in Origin.
RESULTS

**Kinetic Analysis of Bacterial and Human SPTs**

We began by comparing the kinetics of the purified bacterial (SpSPT) and human (scSPT) forms of SPT using “light” L-serine (1) and the commercially available, isotopically-labelled “heavy” L-serine derivatives (2-5) (Fig. 1B). We have carried out comprehensive structural, biochemical and mechanistic studies of *Sphingomonas* SPT (SpSPT) (5, 36) since it was first isolated from bacterial cells (26). The catalytic activity of this recombinant, homodimeric, soluble SpSPT is relatively easy to monitor using a convenient, continuous spectrophotometric assay with the DTNB reagent reacting with released CoASH (6). Importantly, we also confirmed the production of the KDS product using high resolution mass spectrometry to track the incorporation or loss of isotopic labels derived from the various L-serine substrates (see supplemental Fig. S1).

For the SpSPT we have kinetic data using the “light, unlabelled” L-serine (1) from previous studies and the data generated here is in good agreement (L-Ser $K_M = 1.56 \pm 0.10$ mM, specific activity = 386.3 ±39.7 nmol min$^{-1}$ mg$^{-1}$, Fig. 2A, Fig. 2B, Table 1). Carrying out the same analysis with D-, $^{13}$C- and $^{15}$N-labelled L-serine substrates allowed us to determine the impact of the isotopic labels in the substrate on the catalytic activity of the enzyme. As expected, [3,3-D] L-serine (2) behaved essentially the same as the light L-serine version with a $K_M = 2.72 \pm 0.29$ mM and specific activity 396.7 ±13.1 nmol min$^{-1}$ mg$^{-1}$ (p=0.6888, Fig. 2A, Fig. 2B, Table 1). Similarly, [2-$^{13}$C] L-serine (4) also gave equivalent values ($K_M = 3.64 \pm 0.61$ mM, specific activity = 410.6 ±25.5 nmol min$^{-1}$ mg$^{-1}$, p=0.4228, Fig. 2A, Fig. 2B, Table 1). The “heaviest” L-serine ([1,2,3-$^{13}$C, 2-$^{15}$N] (5)), with all three carbons and the amine nitrogen isotopically labelled, also gave comparable data to the lightest version ($K_M = 1.79 \pm 0.20$ mM, specific activity = 440.5 ±17.9 nmol min$^{-1}$ mg$^{-1}$, p=0.0974, Fig. 2A, Fig. 2B, Table 1). In contrast, [2,3,3-D] L-serine (3) with deuterium labels at C2 and C3, showed a substantial decrease in rate and the highest $K_M$ of all substrates tested ($K_M = 4.09 \pm 0.32$ mM and specific activity = 176.9 ±13.0 nmol min$^{-1}$ mg$^{-1}$, p=0.0093 Fig. 2A, Fig. 2B, Table 1).
We also measured the accurate masses of the KDS products derived from each L-serine substrate (Table 2, supplemental Fig. S1). Unlabelled L-serine gives KDS with $m/z = 300.2905$ which is in very good agreement with the empirical formula for the [M+H]$^+$ ion (C$_{18}$H$_{37}$NO$_2$, expected $m/z$ [M+H]$^+$ = 300.2897). The heaviest L-serine substrate, with four isotope labels ([1,2,3-$_{13}$C, 2-$_{15}$N] L-serine, (5)), gives a KDS $m/z = 303.2953$ (C$_{18}$H$_{37}$$_{13}$C$_2$, expected $m/z$ [M+H]$^+$ = 303.2935) which has a nominal $\Delta$mass = +3 compared to the lightest substrate and is consistent with the loss CO$_2$ as expected during the SPT-catalysed reaction (Fig. 1A). [3,3-D] L-serine (2) gives a KDS product with $m/z = 302.3043$ (expected $m/z$ [M+H]$^+$ for C$_{18}$H$_{35}$D$_2$NO$_2$ = 302.3023) that confirms retention of both labels. Similarly, the singularly labelled [2-$_{13}$C] L-serine (4) gave a KDS with $m/z = 301.2944$ (expected $m/z$ [M+H]$^+$ for C$_{18}$H$_{35}$$_{13}$C$_2$NO$_2$ = 301.2931), again consistent with retention of the label. Importantly, the [2,3,3-D] L-serine (3) derived KDS product gave a $m/z = 302.3042$ (expected $m/z$ [M+H]$^+$ for C$_{18}$H$_{35}$D$_2$NO$_2$ = 302.3023), which clearly indicates the loss of a deuterium during the SPT-catalysed reaction (Fig. 1A).

Unlike the bacterial SPT, it is technically difficult to isolate the multi-subunit, ER-membrane bound human SPT complex (15). However, we have been able to purify milligram quantities of recombinant “fused” human single chain SPT (formed by linking the subunits LCB2-ssSPTa-LCB1) from a yeast expression system (Somashekarappa et al., in preparation) (14, 17, 38, 40). This purified scSPT is catalytically active and able to support growth of yeast cells where endogenous SPT activity has been knocked out (38). We used the same L-serine substrate panel (1-5) to measure the rate of the SPT-catalysed reaction for each substrate but unfortunately, it was not possible to measure the $K_M$ for scSPT using the convenient DTNB assay because of the difficulty in detecting activity at low L-serine concentrations – purified scSPT is ~33 fold less active than its purified bacterial SpSPT counterpart (Fig. 2B and 2C, Table 1). However, the rate for each L-serine substrate (1-5) could be determined by having the amino acid substrate at a final concentration of 10 mM in the reaction. The rate with the “light” L-serine substrate (1) was 1161.7 ±125.2 pmol min$^{-1}$ mg$^{-1}$ (Fig. 2C, Table 1). Using a $^3$H L-serine radiolabelled assay we previously reported the activity of scSPT in yeast microsomes (~250 pmol min$^{-1}$ mg$^{-1}$) and CHO-LyB cells (~1500 pmol min$^{-1}$ mg$^{-1}$) (14) as well as HEK293 microsomal preparations (~1500 pmol min$^{-1}$ mg$^{-1}$) (17). This shows the purified scSPT is highly active upon removal
from the microsomal environment. Then, when we measured the rates (12.2 ±0.8, 10.4 ±2.2, 11.3 ±0.8
and 12.9 ±1.9 nmol min⁻¹ mg⁻¹) using each of the “heavy” L-serine substrates (2-5) respectively, we
observed no significant differences (p = 0.5524, 0.4621, 0.7185 and 0.3863 respectively) when
compared to L-serine (1). The MS analysis of the scSPT KDS products (Suppl. Fig. 1) verified that the
human enzyme gave the same incorporation patterns as that observed for the bacterial SPT, including
the loss of a deuterium with the [2,3,3-D] L-serine substrate (3) (Table 2).

To confirm that the observed kinetic data for the single chain SPT were not a result of the enzyme being
removed from its membrane-bound environment or due to the constraints imposed by the fusion
strategy, we also carried out long chain base (LCB) analysis of yeast microsomes containing the
overexpressed three-subunit, single chain scSPT form and the human SPT complex produced by
independent coexpression of the three subunits LCB1, LCB2 and ssSPTa. This analysis was carried out
over a ten minute period and measured the levels of C17 LCB production using a C15-CoA substrate
and L-serine isotopologues 1, 2 and 3 (L-serine, [3,3-D] L-serine and [2,3,3-D] L-serine respectively).
The use of this C15 substrate ensures that the LCB production is derived from a de novo, SPT-catalysed
in vitro reaction. The LCBs were detected using fluorescent LC-derivatisation (Fig. 3) (38). Over this
time course we found that the levels of C17 LCBs produced in microsomal preparations from the scSPT
(2031.6 ±76.1, 1825.9 ±125.0 and 1943.5 ±104.0 pmol mg⁻¹) or the coexpressed subunits (1538.1 ±34.9,
1468.3 ±58.9 and 1381.2 ±14.2 pmol mg⁻¹) with L-serine (1), [3,3-D] L-serine (2) and [2,3,3-D] L-
serine (3) respectively were closely matched. The coexpressed SPT complex displayed ~71-80%
activity when compared with the fusion scSPT, but importantly, the rates were not different when
comparing each of L-serine (1), [3,3-D] L-serine (2) and [2,3,3-D] L-serine (3) (Fig. 3). These data
confirm that neither the fusing together of the three SPT subunits, nor the extraction from the
microsomal membrane environment, is detrimental to the activity of SPT complex.

Kinetic Isotope Effect (KIE) of Isotopically Labelled L-Serine on Human and Bacterial Serine
Palmitoyltransferase
From the primary rate data for both enzymes, we extracted $K_{H}/K_{\text{Isotope}}$ values with each of the four isotope-labelled substrates according to Cleland (32, 33). These KIE values are summarised in Table 3. Interestingly, with human scSPT we did not observe any significant KIE with $K_{H}/K_{D}$ values ranging from 0.95 ±0.12 for ([3,3-D] L-serine, 2), 1.11 ±0.23 ([2,3,3-D] L-serine, 3), 1.03 ±0.14 ([2-13C] L-serine, 4) and 0.90 ±0.18 ([1,2,3-13C, 2-15N] L-serine, 5) when compared to L-serine (1). In contrast, the bacterial SpSPT displayed different kinetics to the human enzyme. Although no significant effect on the reaction rate was observed for labelled L-serine substrates [3,3-D] L-serine (2), [2-13C] L-serine (4) and [1,2,3-13C, 2-15N] L-serine (5) with values of 0.97 ±0.11, 0.94 ±0.12 and 0.87 ±0.11 respectively, we did observe a $K_{H}/K_{\text{Isotope}}$ isotope value of 2.19 ±0.13 for the [2,3,3-D] L-serine substrate (3) which has a deuterium label at C2 (Table 3).

**DISCUSSION**

Isotopically-labelled amino acids have proved useful in studies of SL biosynthesis in various species and cell lines (34, 41-44). However, it is important to recognise that the type and position of the label can significantly influence the underlying kinetics of the pathway being investigated. We used five different isotopically labelled versions of unlabelled “light” L-serine (1) and a range of “heavy” L-serine substrates with deuterium, 13C and 15N labels in specific positions ([3,3-D] L-serine, [2,3,3-D] L-serine, [2-13C] L-serine and [1,2,3-13C, 2-15N] L-serine, 2-5, Fig. 1B), in order to observe what effect, if any, the type and position of these labels have on the kinetics of the enzyme-catalysed reaction. We used purified bacterial SpSPT whose mechanism, kinetics and x-ray structure have been well characterised (5, 6, 23, 24) and compared this cytoplasmic, homodimer with the more complex membrane bound SPT from humans. For this we fused the subunits of human SPT together to form recombinant scSPT, allowing us to control the stoichiometry of the LCB1:ssSPTa:LCB2a subunits as 1:1:1, although the exact natural ratio of the subunits within any eukaryotic SPT complex is still not known.
With SpSPT we observed no noticeable effect on the rate with labelled L-serine substrates [3,3-D] L-serine, [2-13C] L-serine and [1,2,3-13C, 2-15N] L-serine (2, 4 and 5), which was expected since none of the isotopes were in a position where they would influence catalysis based on the proposed SPT mechanism (Fig. 1A). However, in the presence of [2,3,3-D] L-serine (3), the rate of the reaction was decreased by ~50%. We derived a KIE (K_H/K_D) of 2.18 ±0.13 for this reaction using this substrate. When compared to the reaction in the presence of [3,3-D] L-serine (2), for which we derived no discernible KIE, it can clearly be seen that the presence of a deuteron at the C-α position (C2) of the amino acid affects the rate of the reaction. This demonstrates that this deprotonation step is partially rate determining in the SpSPT-catalysed reaction. In contrast to the bacterial homologue, the rates of the human scSPT-catalysed reaction were unaffected regardless of the type or position of the isotope in the L-serine substrate.

We confirmed that the absence of a KIE with human scSPT was not an artefact of our fusion strategy nor was it due to having removed the enzyme from its native membrane environment. We did this by measuring in vitro SPT activity in microsomes prepared from yeast lacking endogenous SPT and expressing either the scSPT or the three independent subunits (LCB1, LCB2a and ssSPTa) of human SPT. Using C15 acyl-CoA as substrate, de novo SPT activity was measured by quantitating the C17 LCBs since yeast does not produce C15-CoA and C17 LCBs. Our data show no difference in the levels of C17 LCBs regardless of whether L-serine (1), [3,3-D] L-serine (2) or [2,3,3-D] L-serine (3) was used with either of the microsomal SPTs, validating the results obtained with purified human scSPT.

Examination of the proposed SPT reaction mechanism and comparison with those put forward for the other AOS family members provides a rationale for the observed KIEs (Fig. 1A). Formation of the substrate quinonoid requires deprotonation by an active site base at C2, a process which is initiated by binding of the second substrate, palmitoyl-CoA (25). As such, it is not surprising that replacement of the α-proton with a deuterium (with [2,3,3-D] L-serine 3) would alter the rate of the reaction. In SpSPT, from the KIE data, it is clear that this deprotonation is at least a partially, if not completely, rate-determining step. However, it is surprising that this is not the case in human SPT. As well as being membrane-bound, the other major difference between the SPTs from prokaryotes and eukaryotes is the
influence of a set of ssSPT isoforms (ssSPTa/b in mammals and Tsc3p in yeast). These small subunits have been shown to not only increase the rate of the mammalian SPT-catalysed reaction by ~100 fold but also control the acyl-CoA substrate specificity of the enzyme with the ssSPTa subunit conferring C16-CoA specificity and ssSPTb conferring both C16 and C18 acyl-CoA chain selectivity (13, 14, 45). We speculate whether the presence of the ssSPTa subunit in our fusion SPT construct is responsible for changing the rate limiting step of the reaction. However, an atomic level structure is needed to confirm that this is the case. With regards to substrates [3,3-D] L-serine (2), [2-13C] L-serine (3) and [1,2,3-13C, 2-15N] L-serine (5), none of these compounds have deuterium labels in bond making or breaking positions so no KIE would be expected. The effect, if any, of the 15N and 13C labels is either low or not observed, since KIEs for 15N and 13C are not as pronounced, due to the smaller change in mass between 14N-15N and 12C-13C (44, 45). While it might be argued that the fusion SPT construct does not behave like native SPT, several lines of evidence indicate that it does. For example, changing a single amino acid in the ssSPTa within the scSPT shifts the acyl-CoA substrate preference analogously to what is observed for the heterotrimeric SPT (14). Similarly, introducing the HSAN1 SPTLC1 C133W mutation into the scSPT confers promiscuity for the amino acid substrate (38). Finally, the fusion SPT is regulated by the ORMDLs similarly to the heterotrimeric SPT (17, 19).

Isotopically-labelled substrates have been used to investigate the mechanism of other AOS family members, such as E. coli KBL, in which R/S [2-3H, 2-14C] labelled glycine and acetyl-CoA were used to show that the enzyme selectively removes the pro-R proton at C-α (46). Ferreira and colleagues have used deuterated glycine (at C-α) to investigate the Rhodococcus capsulata ALAS-catalysed reaction of glycine with succinyl-CoA (47, 48). In these reactions, a KIE of 1.2 (K_H/K_D) was determined, indicating that in ALAS abstraction of the C-α proton is not rate limiting. Similarly with the AONS from Bacillus subtilis, Ploux and Marquet used deuterium-labelled C-α L-alanine to calculate a KIE (K_H/K_D) of 1.3 for the AONS-catalysed reaction of L-alanine with pimeloyl-CoA (49). Both the KIEs for AONS and ALAS are noticeably lower than for SPT, indicating that the SPT mechanism is subtly different when compared to other members of the AOS family.
In a recent complementary study of the yeast SPT, Hannun and colleagues used tandem mass spectrometry to observe SPT-catalysed KDS formation and reduction to dihydrophosphogosine (DHS, presumably by the endogenous KDS-reductase) in yeast microsomes in which the SPT subunits (LCB1, LCB2, and small subunit, Tsc3p) were not overexpressed but present at endogenous levels (34). Interestingly, they did not observe an effect on the rate of the *S. cerevisiae* SPT-catalysed reaction for either [3,3-D] L-serine (2) or [2,3,3-D] L-serine (3), in agreement with the data we obtained for human scSPT. Since these assays were conducted in a native microsomal environment, we assume that Tsc3p, the yeast small subunit, would have been present. Taken together this suggests that the respective small subunits, Tsc3p in yeast SPT and ssSPTa/b in human SPT, could well be responsible for the difference in kinetics we observe between the bacterial and eukaryotic SPTs. Another intriguing aspect of the SPT complex is the impact of HSAN1 disease-causing mutations in SPTLC1 and SPTLC2 that increase the basal activity of the SPTLC1/SPTLC2 heterodimer (14, 50, 51). Based on these observations, we have argued that the penalty for mutationally increasing SPT activity of the heterodimer is loss of amino acid substrate specificity and that a major role of the ssSPTs is to increase enzymatic activity without compromising amino acid selectivity. This is consistent with the possibility that deprotonation is rate-limiting for the heterodimer and that the HSAN1 mutations lead to a change in the rate-limiting step enhanced deprotonation of L-serine as well as of alanine and glycine. Indeed, we have reported that the SPTLC1 C133W HSAN1 mutation does not affect the binding affinity of L-alanine, but rather the rate of condensation of L-alanine with palmitoyl-CoA (38).

In conclusion the use of labelled serine derivatives is a powerful tool for studying SL biosynthesis in various organisms (31, 41, 42, 52). Our studies with the human enzyme (and by others with the yeast isoform (34)) validate [2,3,3-D] L-serine (3) as a useful tool. However, using purified bacterial SPT we have observed that there is a kinetic penalty for the use of a deuterium at Cα. In addition, since the label is lost regardless of the SPT isoform, we conclude that there is no practical use in SPT assays for a L-serine substrate with a deuterium label on C2. Although bacterial SpSPT and human scSPT catalyse the formation of the same KDS product, there are clearly different kinetics at play and these appear to be dependent on the presence of the small-subunit. This also demonstrates that without first investigating
the effects of a label on the reaction, one could possibly pay a heavy kinetic price as was observed with SpSPT (45). Where a label is required, we recommend that substrates containing either $^{13}\text{C}$ or $^{15}\text{N}$ labels be explored, since if these atoms are involved in rate determining steps, the kinetic penalty is less.

This work was supported by a grant from the Biotechnology and Biological Sciences Research Council (BBSRC, BB/M003493/1) to DJC and by CHIRP 70-3155 grant to TMD. Mass spectrometry analysis was acquired an instrument funded by an Engineering and Physical Sciences Research Council (EPSRC) grant to the University of Edinburgh (EP/K039717/1).

REFERENCES


<table>
<thead>
<tr>
<th></th>
<th>SpSPT</th>
<th>scSPT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>KM</td>
<td>Rate</td>
</tr>
<tr>
<td></td>
<td>(mM)</td>
<td>(nmol min(^{-1}) mg(^{-1}))</td>
</tr>
<tr>
<td>1 L-Serine</td>
<td>1.56 ±0.10</td>
<td>386.3 ±39.7</td>
</tr>
<tr>
<td>2 [3,3-D] L-Serine</td>
<td>2.72 ±0.29</td>
<td>396.7 ±13.1</td>
</tr>
<tr>
<td>3 [2,3,3-D] L-Serine</td>
<td>4.09 ±0.32</td>
<td>176.9 ±13.0</td>
</tr>
<tr>
<td>4 [2-(^{13})C] L-Serine</td>
<td>3.64 ±0.61</td>
<td>410.6 ±25.5</td>
</tr>
<tr>
<td>5 [1,2,3-(^{13})C, 2-(^{15})N] L-Serine</td>
<td>1.79 ±0.20</td>
<td>440.5 ±17.9</td>
</tr>
</tbody>
</table>

**Table 1.** Kinetic parameters ($K_M$ and rate for SpSPT, rate for ScSPT) verses different serine isotopologues
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 L-Serine</td>
<td>300.2897</td>
<td>300.2905 300.2928</td>
<td>C_{18}H_{37}NO_2</td>
</tr>
<tr>
<td>2 [3,3-D] L-Serine</td>
<td>302.3023</td>
<td>302.3044 302.3045</td>
<td>C_{18}H_{32}D_2NO_2</td>
</tr>
<tr>
<td>3 [2,3,3-D] L-Serine</td>
<td>302.3023</td>
<td>302.3042 302.3048</td>
<td>C_{18}H_{34}D_3NO_2</td>
</tr>
<tr>
<td>4 [2-{^{13}C}] L-Serine*</td>
<td>301.2931</td>
<td>301.2944 301.2955</td>
<td>^{13}C_1C_1H_{37}NO_2</td>
</tr>
<tr>
<td>5 [1,2,3-{^{13}C}, 2-{^{15}N}] L-Serine*</td>
<td>303.2935</td>
<td>303.2932 303.2955</td>
<td>^{13}C_2C_16H_{37}N_1O_2</td>
</tr>
</tbody>
</table>

* Mass of KDS product derived from [2-{^{13}C}] L-serine (4) accounts for loss of alpha-carbon deuterium

# Mass of KDS product derived from [1,2,3-{^{13}C}, 2-{^{15}N}] L-serine (5) accounts for loss of ^{13}C isotope as a result of decarboxylation during KDS formation

**Table 2.** Expected (assuming retention of all isotope labels) and observed masses of 3-KDS products.
<table>
<thead>
<tr>
<th>Substrate</th>
<th>(K_{H}/K_{\text{Isotope}})</th>
<th>SpSPT</th>
<th>scSPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2  [3,3-D] L-Serine</td>
<td>0.97 ±0.11</td>
<td>0.95 ±0.12</td>
<td></td>
</tr>
<tr>
<td>3  [2,3,3-D] L-Serine</td>
<td>2.18 ±0.13</td>
<td>1.11 ±0.23</td>
<td></td>
</tr>
<tr>
<td>4  [2-\text{\textsuperscript{13}} C] L-Serine</td>
<td>0.94 ±0.12</td>
<td>1.03 ±0.14</td>
<td></td>
</tr>
<tr>
<td>5  [1,2,3-\text{\textsuperscript{13}} C, 2-\text{\textsuperscript{15}} N] L-Serine</td>
<td>0.88 ±0.11</td>
<td>0.90 ±0.18</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3.** KIE values (\(K_{H}/K_{\text{Isotope}}\)) determined for the reactions of purified SpSPT and ScSPT against isotopically labelled L-serine.
Fig. 1. A. The proposed mechanism of serine palmitoyltransferase (SPT). Briefly, L-serine binds to the PLP-bound, internal aldimine, displacing the active site lysine to form the SPT PLP:L-serine external aldimine complex. Binding of palmitoyl-CoA induces a conformational change which causes removal of the α-proton from L-serine to form the PLP:L-serine quinonoid. The quinonoid attacks the palmitoyl-
CoA thioester and leads to C-C bond formation which, after electron rebound, results in CoAS release and formation of the β-keto acid intermediate. Decarboxylation leads to the PLP-bound product quinonoid, which is reprotonated by an active site acid. The active site lysine then displaces the 3-KDS product and reforms the internal aldimine with PLP bound. B. Isotope labelling patterns of L-serine substrates used in this study. Each isotopologue is labelled with appropriate heavy atom (deuterium D), $^{13}$C or $^{15}$N denoted by an asterisk. L-serine (1) and (5) are referred to as “light” and “heavy” respectively.
Fig. 2. Rates of SpSPT and scSPT catalysed reactions in the presence of L-serine isotopologues (1-5).

A. Initial rate of SpSPT catalysed reaction of L-serine isotopologues at varying concentrations with 250 µM palmitoyl-CoA. (1) L-serine, (2) [3,3-D] L-serine, (3) [2,3,3-D] L-serine, (4) [2-13C] L-serine, (5) [1,2,3-13C, 2-15N] L-serine. B. Rate of purified SpSPT and C rate of purified scSPT. Both B and C were carried out with 10 mM L-serine substrates (1–5) and 250 µM palmitoyl-CoA.
Fig. 3. Quantification of C17-LCBs produced by yeast membranes. The membranes were prepared from cells expressing scSPT (black boxes) or co-expressing Lcb1 + Lcb2 + ssSPTa (grey boxes). Yeast membranes were incubated with L-serine isotopologues 1, 2 and 3 along with 100 μM pentadecanoyl coenzyme-A (C15-CoA) to generate the C17-LCBs. The products were derivatized with AccQ-Fluor reagent and analysed by HPLC and fluorescent detection.